Literature DB >> 22915241

Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy.

Amber M D'Souza1, Kamal S Pohar, Tahir Arif, Susan Geyer, Debra L Zynger.   

Abstract

A range of studies have analyzed prognostic factors in bladder cancer. However, prior cohorts have included heterogeneous pT classification at biopsy and others were derived from large, multi-institutional clinical trials over the span of many years. Our objective was to analyze prognostic factors in a recent radical cystectomy (RC) cohort at a single institution and evaluate outcomes based on current practice patterns. A retrospective analysis of overall survival (OS) was conducted on 180 RC patients with biopsy proven pT2 disease between 2007-2010. Increasing pT classification was a negative predictor of survival. pT was grouped into three categories with pT0/a/is/1/2a surviving longer than pT2b/3a/3b, and pT4 having the worst prognosis. Subclassifying pT2 and pT3 showed no statistically significant difference in survival. Lymphovascular invasion (LVI) and node positivity correlated with decreased OS. Patients treated with neoadjuvant chemotherapy (NAC) had a higher incidence of pT0, yet pN1+ was more common and NAC was not associated with improved OS. This investigation provides reference OS values for patients with pathologically diagnosed muscle-invasive bladder cancer based on current medical guidelines outside the context of a clinical trial. pT4 was the strongest negative predictor of survival, followed by pN1+, the group pT2b/3a/3b, and presence of LVI. NAC patients were noted to have a higher frequency of low pT classification, yet more frequent node positivity, suggesting that pT classification in NAC patients may not accurately reflect remaining tumor burden.

Entities:  

Mesh:

Year:  2012        PMID: 22915241     DOI: 10.1007/s00428-012-1249-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.

Authors:  Derya Tilki; Robert S Svatek; Giacomo Novara; Michael Seitz; Guilherme Godoy; Pierre I Karakiewicz; Wassim Kassouf; Yves Fradet; Hans-Martin Fritsche; Guru Sonpavde; Jonathan I Izawa; Vincenzo Ficarra; Seth P Lerner; Mark Schoenberg; Christian G Stief; Colin P Dinney; Eila Skinner; Yair Lotan; Arthur I Sagalowsky; Oliver Reich; Shahrokh F Shariat
Journal:  J Urol       Date:  2010-09       Impact factor: 7.450

2.  Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.

Authors:  R James Yu; John P Stein; Jie Cai; Gus Miranda; Susan Groshen; Donald G Skinner
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

3.  Can immunohistochemistry enhance the detection of micrometastases in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder?

Authors:  X J Yang; K Lecksell; J I Epstein
Journal:  Am J Clin Pathol       Date:  1999-11       Impact factor: 2.493

4.  Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2.

Authors:  Amir Sherif; Erkki Rintala; Oddvar Mestad; Jonas Nilsson; Lars Holmberg; Sten Nilsson; Per-Uno Malmström
Journal:  Scand J Urol Nephrol       Date:  2002

5.  A predictive model of survival after radical cystectomy for carcinoma of the bladder.

Authors:  M A Ghoneim; M M El-Mekresh; A A Mokhtar; M A Gomha; M A El-Baz; I A El-Attar
Journal:  BJU Int       Date:  2000-05       Impact factor: 5.588

6.  Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy.

Authors:  Daniel Canter; Christopher Long; Alexander Kutikov; Elizabeth Plimack; Ismail Saad; Megan Oblaczynski; Fang Zhu; Rosalia Viterbo; David Y T Chen; Robert G Uzzo; Richard E Greenberg; Stephen A Boorjian
Journal:  BJU Int       Date:  2011-01       Impact factor: 5.588

7.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

Authors:  Stephan Madersbacher; Werner Hochreiter; Fiona Burkhard; George N Thalmann; Hansjörg Danuser; Regula Markwalder; Urs E Studer
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

8.  Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed.

Authors:  Murugesan Manoharan; Devendar Katkoori; Thekke A Kishore; Bruce Kava; Rakesh Singal; Mark S Soloway
Journal:  BJU Int       Date:  2009-05-19       Impact factor: 5.588

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

Review 10.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

View more
  3 in total

1.  In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance.

Authors:  Nadine T Gaisa; Holger Wilms; Peter J Wild; Gerhard Jakse; Axel Heidenreich; Ruth Knuechel
Journal:  Virchows Arch       Date:  2015-02-13       Impact factor: 4.064

2.  Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.

Authors:  Izak Faiena; Amirali Salmasi; Neil Mendhiratta; Andrew T Lenis; Aydin Pooli; Alexandra Drakaki; Kiran Gollapudi; Jeremy Blumberg; Allan J Pantuck; Karim Chamie
Journal:  World J Urol       Date:  2018-05-11       Impact factor: 4.226

3.  PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer.

Authors:  Firas Aljabery; Gunnar Lindblom; Susann Skoog; Ivan Shabo; Hans Olsson; Johan Rosell; Staffan Jahnson
Journal:  BMC Urol       Date:  2015-08-21       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.